RESUMEN
The aim of this study was to test the extract from silver fir wood (Belinal) on the reduction of the blood glucose concentrations after consumption of a standard meal. 31 healthy participants consumed 100 g of white bread 4 times (with 1 week washout period, consequently) concomitantly with a capsule of Belinal, capsule of chestnut wood extract, placebo or acarbose (active control). Glucose and insulin in the blood were measured before and after the meal. The area under the curve of glucose concentration in blood after the meal was 35 % lower when Belinal was added compared with the placebo group (p = 0.019). Acarbose lowered the area for 43 % (p = 0.002). By this, we proved that the effect of Belinal might be beneficial for prevention of diabetes. This is the first study that provides a scientific rationale for use of silver fir wood extract as food supplement for reduction of health risks connected to type 2 diabetes mellitus.
Asunto(s)
Abies/química , Glucemia/metabolismo , Hipoglucemiantes/farmacología , Extractos Vegetales/farmacología , Adulto , Estudios Cruzados , Método Doble Ciego , Femenino , Índice Glucémico , Voluntarios Sanos , Humanos , Insulina/sangre , Masculino , Periodo Posprandial/efectos de los fármacos , Adulto JovenRESUMEN
Hyperandrogenemia has been the most consistent feature of polycystic ovary syndrome (PCOS). Androgens exert their effects through androgen receptors (ARs). The expansion of the codon CAG trinucleotide repeat polymorphism in exon 1 of the AR gene represents a type of genetic alteration associated with changes in the AR gene function. The purpose of this study was to establish a possible association of the AR gene CAG repeat length polymorphism with PCOS, and its influence on clinical and biochemical androgen traits. Two hundred and fourteen Croatian women with PCOS and 209 healthy control women of reproductive age were enrolled. Phenotypic hyperandrogenism, BMI and waist to hip ratio were recorded. Hormonal profiles, fasting insulin and glucose levels were measured on cycle days 3-5. Genotyping of the CAG repeat polymorphism in the AR gene was performed. We found no significant difference in the mean CAG repeat number between the PCOS patients and controls (22.1±3.4 vs. 21.9±3.2, P=0.286). There was a positive correlation between the CAG repeat length and total testosterone (TT) in the PCOS group (R=0.225, P=0.015). A multiple linear regression model using mean CAG repeat length, BMI, age and HOMA-IR as predictors explained 8.5% (adjusted R²) of the variability in serum TT levels. In this model the CAG repeat polymorphism was found to be a significant predictor of serum TT levels in PCOS patients (P=0.015). The logistic regression analysis revealed that the CAG repeat length is not a significant predictor of hirsutism and acne status (P=0.921 and P=0.437, respectively). The model was adjusted for serum TT, free testosterone, androstendione and DHEAS levels as independent variables, which were also not found to be significant predictors of hirsutism (P=0.687, P=0.194, P=0.675 and P=0.938, respectively) or acne status (P=0.594, P=0.095, P=0.290 and P=0.151, respectively). In conclusion, the AR CAG repeat polymorphism is not a major determinant of PCOS in the Croatian population, but it is a predictor of serum TT level variability in women with PCOS.
Asunto(s)
Síndrome del Ovario Poliquístico/sangre , Síndrome del Ovario Poliquístico/genética , Polimorfismo Genético , Receptores Androgénicos/genética , Testosterona/sangre , Repeticiones de Trinucleótidos , Adulto , Factores de Edad , Índice de Masa Corporal , Croacia , Exones , Femenino , Frecuencia de los Genes , Estudios de Asociación Genética , Humanos , Hiperandrogenismo , Resistencia a la Insulina , Modelos Genéticos , Sobrepeso/complicaciones , Síndrome del Ovario Poliquístico/complicaciones , Síndrome del Ovario Poliquístico/fisiopatología , Receptores Androgénicos/química , Adulto JovenRESUMEN
OBJECTIVE: The study aimed to investigate the influence of some generally recognized risk factors for hormone receptor (HR)- and human epidermal growth factor receptor 2 (HER2)-defined breast cancer among Slovenian postmenopausal women. METHOD: Eligible women diagnosed with breast cancer were compared with 709 controls of the same age and ethnicity. Immunohistochemistry and FISH analyses were used to classify cases into molecular subtypes: 454 HR(+), 106 HR(-), 81 HER2(+) and 603 HER2(-). Adjusted odds ratios and 95% confidence intervals were estimated using multivariate logistic regression analysis. RESULTS: Overweight and obese women were at increased risk of HR(+), HER2(-) and of HR(+), HR(-), HER2(-) tumors, respectively. Women who started menstruating at the age of 11 years or earlier were at decreased risk of ER(-)PR(-) tumors. Users of hormone replacement therapy (HRT) were negatively associated with HR(+) and HER2(-) tumors. The inverse effect was most pronounced with the use of estrogen-only HRT, and longer duration of HRT use did not result in a significant change in risk. In contrast, combined HRT decreased the risk of HER2(+) tumors. Having a first-degree relative with breast and/or ovarian cancer increased the risk of HR(+) and HER2(-) tumors. CONCLUSION: We conclude that certain breast cancer risk factors may vary by molecular subtypes. According to our results, HRT use may have a greater influence on HR (+) and HER2(-) breast cancers and the risk of HER2-defined breast cancer may differ with respect to the regimen of HRT.
Asunto(s)
Neoplasias de la Mama , Terapia de Reemplazo de Estrógeno , Receptor ErbB-2/metabolismo , Receptores de Estrógenos/metabolismo , Receptores de Progesterona/metabolismo , Factores de Edad , Anciano , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/metabolismo , Intervalos de Confianza , Terapia de Reemplazo de Estrógeno/efectos adversos , Terapia de Reemplazo de Estrógeno/métodos , Terapia de Reemplazo de Estrógeno/estadística & datos numéricos , Femenino , Humanos , Inmunohistoquímica , Hibridación Fluorescente in Situ , Menarquia , Persona de Mediana Edad , Obesidad/epidemiología , Oportunidad Relativa , Órganos en Riesgo , Neoplasias Ováricas/diagnóstico , Neoplasias Ováricas/epidemiología , Neoplasias Ováricas/metabolismo , Factores de Riesgo , Eslovenia/epidemiología , TiempoRESUMEN
Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with increased prevalence of insulin resistance (IR). IR could be implicated in PCOS etiology and represents the major cause of cardiometabolic complications. The aim of present study was to investigate for the first time the association of lipin 1 gene polymorphisms with metabolic and hormonal profile in PCOS patients and controls. Into a case-control study 371 individuals were enrolled: 222 PCOS patients and 149 controls. Two lipin 1 gene polymorphisms were analyzed: rs11693809 (intron 1 SNP) and rs2716610 (intron 17 SNP) using fluorescent hydrolyzing probes. Body mass index, fasting plasma insulin and glucose along with androgen profile were measured in all subjects. Plasma lipids were measured in 93 patients and 43 controls and oral glucose test (OGTT) was performed on 68 PCOS patients. C/T heterozygotes for intron 1 SNP had significantly lower LDL-cholesterol than wild type C/C homozygotes (p=0.026) in the control group. In PCOS patients, mutated T/T homozygotes exhibited significantly lower glucose after OGTT than heterozygotes (p=0.033). Similarly, in nonobese PCOS patients, intron 1 SNP T/T homozygotes had lower HOMA-IR than heterozygotes (p=0.009). For intron 17 SNP, mutated C/T+T/T genotypes were associated with higher plasma triglycerides in controls (p=0.039). Genotype and allele frequencies were similar between PCOS patients and controls for both SNPs. Our results show that, in PCOS patients, intron 1 SNP is protective against IR and glucose intolerance suggesting that lipin 1 variation could be one of the genetic factors in cardiometabolic complications of PCOS.
Asunto(s)
Predisposición Genética a la Enfermedad , Fosfatidato Fosfatasa/genética , Síndrome del Ovario Poliquístico/genética , Polimorfismo de Nucleótido Simple/genética , Adulto , Glucemia/metabolismo , Estudios de Casos y Controles , LDL-Colesterol/sangre , Femenino , Frecuencia de los Genes/genética , Prueba de Tolerancia a la Glucosa , Haplotipos/genética , Humanos , Intrones/genética , Fenotipo , Síndrome del Ovario Poliquístico/sangre , Triglicéridos/sangre , Adulto JovenRESUMEN
OBJECTIVE: The aim of the study was to examine the influence of the use of hormone replacement therapy (HRT) and of some generally recognized risk factors on breast cancer risk among Slovenian postmenopausal women. METHODS: Eligible women diagnosed with breast cancer and a control group of women of the same age and ethnicity were invited to participate in the case-control study via a personal letter and asked to complete a written questionnaire. Adjusted odds ratios and 95% confidence intervals were estimated using multivariate logistic regression analysis. RESULTS: A total of 784 cases and 709 controls aged 50-69 years were enrolled. HRT use was inversely associated with breast cancer risk. The effect was most pronounced with the use of estrogen-only replacement therapy (odds ratio (OR) 0.51, 95% confidence interval (CI) 0.30-0.87). Longer duration of HRT use did not result in a significant change in risk (1 to <5 years of HRT use: OR 0.44, 95% CI 0.26-0.73; ≥ 5 years of HRT use: OR 0.51, 95% CI 0.30-0.87). Obesity (25 ≤ body mass index <30 kg/m(2): OR 1.34, 95% CI 1.04-1.73; body mass index ≥ 30 kg/m(2): OR 1.89, 95% CI 1.36-2.63), smoking ≥ 10 cigarettes per day (OR 1.70, 95% CI 1.20-2.43), and any first-degree relative with breast or ovarian cancer (OR 1.52, 95% CI 1.11-2.08) were positively associated with breast cancer risk. CONCLUSIONS: Our analysis revealed some differences from the previously published literature, which might reflect underlying demographic changes. Comprehensive medical care in HRT users without pre-existing breast abnormalities probably reduces the incidence of new breast cancer cases in Slovenia.
Asunto(s)
Neoplasias de la Mama/epidemiología , Terapia de Reemplazo de Estrógeno/efectos adversos , Posmenopausia , Anciano , Índice de Masa Corporal , Neoplasias de la Mama/genética , Estudios de Casos y Controles , Femenino , Humanos , Persona de Mediana Edad , Oportunidad Relativa , Factores de Riesgo , Eslovenia/epidemiología , Fumar/efectos adversos , Encuestas y CuestionariosRESUMEN
Insulin resistance is one of the main characteristics of polycystic ovary syndrome (PCOS) and is probably genetically predisposed. Possible associations of variable nucleotide tandem repeat (VNTR) polymorphism of the insulin gene (INS) with insulin resistance and PCOS in Slovene patients were investigated. A total of 117 PCOS patients and 108 age-matched female controls were genotyped for the INS VNTR polymorphism using real-time polymerase chain reaction and measurement of appropriate biochemical and clinical parameters. Serum fasting insulin (I(0)) levels and the homeostasis model assessment index were significantly elevated in PCOS patients compared with controls. Class III INS VNTR alleles were significantly more frequent in the PCOS group. The interaction between body mass index and INS VNTR genotype was a significant predictor of serum I(0) level. The interaction of obesity and the III/III INS VNTR genotype might be a risk factor for the development of PCOS.